Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer

Fig. 1

Alternative-splicing and expression changes elicited in 22Rv1 cells by treatment with Indisulam, Pladienolide B and THZ531. A Schematic representation of the experimental workflow and RNA-seq analysis performed in 22Rv1cells (PladB, pladienolide B). B Bar graphs representing the % of genes of 22Rv1 transcriptome regulated at either alternative splicing (AS, left panel) or gene-expression (GE, right panel) level. C Venn diagrams showing the overlap between genes regulated at AS and GE level by indicated treatment. For GE-regulated genes, either exclusively or in the overlap with AS, % of up- and down-regulated genes are indicated. D, E Venn diagrams showing the overlap for GE (D) and AS (E) regulated genes by the indicated drugs in 22Rv1 cells respect to control. F Bar graph illustrating the GO terms relative to biological processes significantly enriched within the AS regulated genes by all drugs in (E) (analysis performed with Enrichr tool, p-value < 0,05)

Back to article page